Nasodine Throat Spray Debuts in Singapore, Plans 2026 Rollouts to Fiji and USA

A Strategic Step into International Markets

Firebrick Pharma Limited (ASX, FRE) has taken a significant stride in its commercial journey with the launch of Nasodine Throat Spray in Singapore, its first international market debut. This launch follows the successful manufacturing and shipment of the product from Australia late last year, signalling Firebrick’s commitment to expanding its footprint beyond domestic borders.

The throat spray, formulated with 1% povidone-iodine, is designed to provide targeted relief for sore throats, often an early symptom of the common cold. It complements the company’s existing Nasodine Nasal Spray, which has already established a presence in several markets including the United States and Fiji.

Innovative Product Design and Market Positioning

Unlike traditional gargles, Nasodine Throat Spray offers a compact, easy-to-use, and pleasant tasting solution that is convenient for on-the-go use. Its precise nozzle delivers a low volume spray directly to the affected area, eliminating the need to spit out excess solution and avoiding the inconvenience and staining associated with gargles.

Firebrick’s Executive Chairman, Dr Peter Molloy, emphasised the product’s role in providing a comprehensive nasal and oral approach to cold relief. The launch strategy in Singapore, executed through exclusive licensing partner Innorini Life Sciences, initially targets hospitals and healthcare professionals before expanding to retail channels, reflecting a measured approach to market penetration.

Ambitious Growth Plans for 2026 and Beyond

Following Singapore, Firebrick plans to introduce Nasodine Throat Spray in Fiji and the United States within the year, with further international markets to follow where the nasal spray is already approved. The company also signals the development of additional Nasodine products slated for release in 2026, aiming to build a multi-product franchise across multiple markets.

Innorini’s Managing Director, Rishi Nandiraju, expressed optimism about the brand’s potential to become a trusted household name in Singapore, highlighting strong opportunities across both healthcare and retail sectors.

While the product is not approved for sale in Australia, regulatory frameworks in Singapore allow for its marketing as an antiseptic without prior approval, facilitating a smoother entry into that market. Firebrick has secured the necessary export permits from Australian authorities, underscoring the regulatory diligence behind the launch.

Looking Ahead

Firebrick’s Nasodine Throat Spray launch represents more than just a new product release; it is a strategic move to establish a broader antiseptic care franchise. The company’s ability to navigate diverse regulatory environments and build partnerships will be critical as it seeks to capture market share in competitive healthcare sectors globally.